Should I buy or sell Tango Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TNGX shares. View TNGX analyst ratings or view top-rated stocks .

What is Tango Therapeutics' stock price target for 2024?

5 brokers have issued 12 month price targets for Tango Therapeutics' shares. Their TNGX share price targets range from $16.00 to $18.00. On average, they expect the company's stock price to reach $17.25 in the next year. This suggests a possible upside of 134.1% from the stock's current price. View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts .

How have TNGX shares performed in 2024?

Tango Therapeutics' stock was trading at $9.90 on January 1st, 2024. Since then, TNGX stock has decreased by 25.6% and is now trading at $7.37. View the best growth stocks for 2024 here .

When is Tango Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our TNGX earnings forecast .

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) released its earnings results on Monday, March, 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04. The business had revenue of $5.43 million for the quarter, compared to the consensus estimate of $7.86 million. Tango Therapeutics had a negative net margin of 278.55% and a negative trailing twelve-month return on equity of 41.96%.

What ETF holds Tango Therapeutics' stock?

Range Cancer Therapeutics ETF holds 34,808 shares of TNGX stock, representing 1.18% of its portfolio.

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Mass General Brigham Inc (0.33%). Insiders that own company stock include Adam Crystal, Barbara Weber, Boxer Capital, Llc, Daniella Beckman, Douglas Barry and Rock Ventures Iv LP Third. View institutional ownership trends .

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TNGX

Tango Therapeutics (TNGX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free TNGX Stock Alerts

$7.37

-0.09 (-1.21%)

(As of 04/18/2024 ET)

Compare

Today's Range: $7.31
▼
$7.60
50-Day Range: $7.32
▼
$12.41
52-Week Range: $2.47
▼
$13.03

Volume: 396,770 shs
Average Volume: 660,014 shs
Market Capitalization: $786.53 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.25

Get Tango Therapeutics alerts:

Tango Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 134.1% Upside
$17.25 Price Target
Short Interest: Bearish
19.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.23
Based on 12 Articles This Week
Insider Trading: Selling Shares
$2.10 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.28) to ($1.25) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.84 out of 5 stars

Medical Sector

601st out of 918 stocks

Pharmaceutical Preparations Industry

256th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Tango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Tango Therapeutics has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
19.42% of the float of Tango Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Tango Therapeutics has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Tango Therapeutics has recently increased by 14.75%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tango Therapeutics does not currently pay a dividend.
Dividend Growth
Tango Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TNGX.

3.5

News and Social Media Coverage

News Sentiment
Tango Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Tango Therapeutics this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for TNGX on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tango Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,103,703.00 in company stock.
Percentage Held by Insiders
Only 6.20% of the stock of Tango Therapeutics is held by insiders.
Percentage Held by Institutions
78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Tango Therapeutics are expected to grow in the coming year, from ($1.28) to ($1.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tango Therapeutics is -6.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tango Therapeutics is -6.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tango Therapeutics has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Priority Gold

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

About Tango Therapeutics Stock (NASDAQ:TNGX)

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

TNGX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TNGX Stock News Headlines

April 18, 2024 | americanbankingnews.com

Tango Therapeutics, Inc. Expected to Post Q1 2024 Earnings of ($0.33) Per Share (NASDAQ:TNGX)

April 13, 2024 | americanbankingnews.com

Cantor Fitzgerald Weighs in on Tango Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TNGX)

April 18, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…

April 1, 2024 | businesswire.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 21, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Tango Therapeutics on Strong Pipeline and Financial Stability

March 20, 2024 | finance.yahoo.com

Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results

March 18, 2024 | investorplace.com

TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023

March 18, 2024 | benzinga.com

Recap: Tango Therapeutics Q4 Earnings

April 18, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

March 11, 2024 | finance.yahoo.com

TNGX Aug 2024 20.000 put

March 6, 2024 | businesswire.com

Tango Therapeutics to Participate in Upcoming Investor Conferences

March 5, 2024 | globenewswire.com

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

March 3, 2024 | finance.yahoo.com

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

February 17, 2024 | finance.yahoo.com

TNGX Mar 2024 7.500 call

February 17, 2024 | finance.yahoo.com

TNGX Mar 2024 12.500 call

January 31, 2024 | finance.yahoo.com

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

January 7, 2024 | seekingalpha.com

Tango Therapeutics Must Produce Its Own Data To Justify Its Valuation

January 4, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Tango Therapeutics (TNGX), Esperion (ESPR)

January 4, 2024 | finance.yahoo.com

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

January 3, 2024 | finance.yahoo.com

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers

December 13, 2023 | finance.yahoo.com

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25%

December 8, 2023 | msn.com

B. Riley Securities Initiates Coverage of Tango Therapeutics (TNGX) with Buy Recommendation

December 8, 2023 | realmoney.thestreet.com

Tango Therapeutics initiated with a Buy at B. Riley

December 8, 2023 | finance.yahoo.com

Wall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know

November 13, 2023 | finance.yahoo.com

How Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%

November 13, 2023 | finance.yahoo.com

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

November 10, 2023 | markets.businessinsider.com

Positive Outlook for Tango Therapeutics: Comprehensive Analysis of Ongoing Clinical Trials and Promising PRMT5 Inhibitors

See More Headlines

Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TNGX
CUSIP: N/A
CIK: 1819133
Web: www.tangotx.com
Phone: 857-320-4900
Fax: N/A
Employees: 140
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.25
High Stock Price Target: $18.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +134.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-101,740,000.00
Net Margins: -278.55%
Pretax Margin: -278.18%
Return on Equity: -41.96%
Return on Assets: -25.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.54
Quick Ratio: 7.54

Sales & Book Value

Annual Sales: $36.53 million
Price / Sales: 21.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.48 per share
Price / Book: 2.97

Miscellaneous

Outstanding Shares: 106,720,000
Free Float: 100,101,000
Market Cap: $786.53 million
Optionable: Optionable
Beta: 0.83

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Barbara L. Weber M.D. (Age 66)
President, CEO & Director
Comp: $941.16k
Ms. Daniella Beckman CPA (Age 45)
Chief Financial Officer
Comp: $619.13k
Dr. Alan Ashworth FRS (Age 62)
Ph.D., Founder & Member of Scientific Advisory Board
Dr. Levi Garraway M.D. (Age 55)
Ph.D., Founder
Dr. William G. Kaelin Jr. (Age 66)
M.D., Founder & Member of Scientific Advisory Board
Dr. Timothy K. Lu M.D. (Age 43)
Ph.D., Founder
Dr. Antoni Ribas M.D. (Age 57)
Ph.D., Founder & Member of Scientific Advisory Board
Mr. Jannik N. Andersen Ph.D.
Chief Scientific Officer
Mr. Douglas J. Barry Esq. (Age 54)
J.D., General Counsel, Chief Compliance Officer & Corporate Secretary
Mr. John C. Ross M.S.
Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TNGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings or view top-rated stocks.
What is Tango Therapeutics' stock price target for 2024?: 5 brokers have issued 12 month price targets for Tango Therapeutics' shares. Their TNGX share price targets range from $16.00 to $18.00. On average, they expect the company's stock price to reach $17.25 in the next year. This suggests a possible upside of 134.1% from the stock's current price.
View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts.
How have TNGX shares performed in 2024?: Tango Therapeutics' stock was trading at $9.90 on January 1st, 2024. Since then, TNGX stock has decreased by 25.6% and is now trading at $7.37.
View the best growth stocks for 2024 here.
When is Tango Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our TNGX earnings forecast.

How were Tango Therapeutics' earnings last quarter?: Tango Therapeutics, Inc. (NASDAQ:TNGX) released its earnings results on Monday, March, 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04. The business had revenue of $5.43 million for the quarter, compared to the consensus estimate of $7.86 million. Tango Therapeutics had a negative net margin of 278.55% and a negative trailing twelve-month return on equity of 41.96%.
What ETF holds Tango Therapeutics' stock?: Range Cancer Therapeutics ETF holds 34,808 shares of TNGX stock, representing 1.18% of its portfolio.
Who are Tango Therapeutics' major shareholders?: Tango Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Mass General Brigham Inc (0.33%). Insiders that own company stock include Adam Crystal, Barbara Weber, Boxer Capital, Llc, Daniella Beckman, Douglas Barry and Rock Ventures Iv LP Third.
View institutional ownership trends.
How do I buy shares of Tango Therapeutics?: Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNGX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial